Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
REDWOOD CITY, Calif., May 02, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2017 financial results after market close on Tuesday, May 9, 2017. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 14067412 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 14067412 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
CONTACTS:
Investors
LHA
Jody Cain, 310 691 7100
[email protected]
